PTP
ATXS

Platform Technology Partners’s Astria Therapeutics ATXS Stock Holding History

Platform Technology Partners’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,493
Closed -$195K – 183
2019
Q4 		$195K Buy
+5,493
New +$173K 0.15% 156

Other funds holding ATXS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Platform Technology Partners's ATXS Position: Q1 2020 in Review

Platform Technology Partners sold out of Astria Therapeutics (ATXS) in Q1 2020, closing a stake of 5,493 shares — an estimated $195K sold.

Platform Technology Partners first reported a position in ATXS in Q4 2019 and held it in 1 quarter. The position peaked at $195K in Q4 2019. 27 funds tracked by Wall St. Rank hold ATXS as of Q1 2020.

  • Platform Technology Partners reported no remaining Astria Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Platform Technology Partners sold 5,493 Astria Therapeutics shares in Q1 2020, an estimated $195K.
  • Platform Technology Partners first reported a position in Astria Therapeutics in Q4 2019 and held it in 1 quarter.
  • Platform Technology Partners's Astria Therapeutics position peaked at $195K in Q4 2019.
  • 27 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2020.

Based on Platform Technology Partners's 13F filing for Q1 2020, filed 30 Nov 2020.